Fiscal 2021: Record Growth and Higher Profitability

Fiscal 2021

• Group sales rise by 12.3% to € 19.7 billion; EBITDA pre up 17.3% to € 6.1 billion; EBITDA pre margin increases to 31.0%
• Greater investments in high-growth businesses; net financial debt significantly lower
• Earnings per share pre of € 8.72; proposed dividend rises by € 0.45 to all-time high of € 1.85
  

Forecast for 2022

• Strong organic growth of net sales and EBITDA pre expected
• All business sectors are forecast to contribute to the positive development; Life Science will remain the strongest growth engine of the Group
  

• Quarterly Statement Q4 2021 (Online version)
  
• Quarterly Statement Q4 2021 (PDF)

Downloads for the Media

• Press Release
• Presentation for the Media
• Digital Press Kit (ZIP File)

Additional Downloads

• Presentation for Analysts (PDF)
  
• Financial Statement (XLS)
• Financial Statement (PDF)
  
• Regional Sector Sales (XLS)
• Summary (PDF)